Eileen Egan
Family · Myrtle Beach, SCNPI 1225290364
Payments from drug & device makers
Across 135 payments — averaging $62.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$6K
- BETA Bionics, Inc.$417
- Bayer$199
- Averitas Pharma Inc.$189
- Abbott$170
- Dexcom, Inc.$139
- plus $1K from 25 others
What the payments were for
- Consulting fees$1,59019%
- Speaking & faculty fees$3,45041%
- Food & beverage$3,21638%
- Education$1942%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $5,914 |
| BETA Bionics, Inc. | 4 | $417 |
| Bayer | 6 | $199 |
| Averitas Pharma Inc. | 2 | $189 |
| Abbott | 10 | $170 |
| Dexcom, Inc. | 8 | $139 |
| AbbVie | 8 | $130 |
| Xeris Pharmaceuticals, Inc. | 7 | $112 |
| Sanofi-aventis U.S. LLC | 4 | $111 |
| Lilly USA, LLC | 7 | $110 |
| AstraZeneca | 6 | $107 |
| Tandem Diabetes Care, Inc. | 4 | $95 |
| Insulet Corporation | 4 | $94 |
| Corcept Therapeutics | 4 | $91 |
| Johnson & Johnson | 5 | $78 |
| Daiichi Sankyo Inc. | 3 | $75 |
| Rhythm Pharmaceuticals, Inc. | 2 | $53 |
| IBSA Pharma Inc. | 2 | $43 |
| Cequr Corporation | 3 | $39 |
| Boehringer Ingelheim | 2 | $38 |
| Spinal Simplicity, LLC | 2 | $38 |
| Merck | 2 | $33 |
| Alkermes, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Amgen | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Nevro Corp. | 1 | $16 |
| Mannkind Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,449 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 572 | $956,988 |
| MounjaroTirzepatide | 196 | $345,131 |
| JardianceEmpagliflozin | 172 | $223,067 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 117 | $188,430 |
| FarxigaDapagliflozin Propanediol | 161 | $167,210 |
| TrulicityDulaglutide | 93 | $134,532 |
| Tresiba Flextouch U-100Insulin Degludec | 185 | $116,664 |
| RybelsusSemaglutide | 62 | $107,049 |
| Tresiba Flextouch U-200Insulin Degludec | 77 | $80,850 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 66 | $57,879 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $50,018 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 38 | $40,012 |
| Humalog Kwikpen U-200Insulin Lispro | 33 | $35,661 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $29,524 |
| Humalog Kwikpen U-100Insulin Lispro | 107 | $26,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $5,914 | $1,078,660670 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Insulin Lispro | $110 | $506,498375 claims |
| Boehringer IngelheimJardiance | $38 | $223,067172 claims |
| AstraZenecaFarxiga | $107 | $167,210161 claims |
| MerckJanuvia | $33 | $16,55513 claims |
| Sanofi-aventis U.S. LLCLantus | $111 | $1,96920 claims |
| AbbVieSynthroid | $130 | $1,86836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.
Other family in Myrtle Beach
- Beverly MillerMyrtle Beach$10K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.